Ireland - English - HPRA (Health Products Regulatory Authority)

organon laboratories limited - testosterone propionate testosterone phenylpropionate testosterone isocaproate - solution for injection - 20/40/40 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

organon laboratories limited - testosterone propionate testosterone phenylpropionate testosterone isocaproate testosterone decanoate - solution for injection - 30/60/60/1 mg/ml

Malta - English - Medicines Authority

alliance pharmaceuticals limited avonbridge house, bath road, chippenham, wiltshire sn15 2bb, united kingdom - testosterone enanthate - solution for injection - testosterone enanthate 250 mg/ml - sex hormones and modulators of the genital system

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon laboratories ltd - testosterone propionate; testosterone phenylpropionate; testosterone isocaproate - solution for injection - 20mg/1ml ; 40mg/1ml ; 40mg/1ml

United States - English - NLM (National Library of Medicine)

eugia us llc - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate injection in men with “age­-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. 1.   known hypersensitivity to the drug 2.   males with carcinoma of the breast 3.   males with known or suspected carcinoma of the prostate gland 4.   women who are pregnant (see precautions, pregnancy ) 5.   patients with serious cardiac, hepatic or renal disease (see warnings ) testosterone cypionate injection contains testosterone, a schedule iii c

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. - hypogonadotropic hypogonadism (congenital or acquired)-gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. 1. known hypersensitivity to the drug 2. males with carcinoma of the breast 3. males with known or suspected carcinoma of the prostate gland 4. women who are pregnant (see precautions, pregnancy) 5. patients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule iii controlled substance in the

Canada - English - Health Canada

pfizer canada ulc - testosterone cypionate - solution - 100mg - testosterone cypionate 100mg - androgens

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone 30 mg in 1.5 ml - axiron is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (fsh, lh) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations but have gonadotropins in the normal or low range. important limitations of use — safety and efficacy of axiron in males <18 years old have not been established [see use in specific populations (8.4)] . - axiron is contraindicated in

United States - English - NLM (National Library of Medicine)

aleor dermaceuticals limited - testosterone (unii: 3xmk78s47o) (testosterone - unii:3xmk78s47o) - testosterone topical solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. - primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. these men usually have low serum testosterone concentrations and gonadotropins (fsh, lh) above the normal range. - hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (lhrh) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. these men have low testosterone serum concentrations but have gonadotropins in the normal or low range. limitations of use: - safety and efficacy of testosterone topical solution in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been estab

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - testosterone cypionate (unii: m0xw1ubi14) (testosterone - unii:3xmk78s47o) - testosterone cypionate 200 mg in 1 ml - testosterone cypionate injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or lhrh deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. safety and efficacy of testosterone cypionate in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. - known hypersensitivity to the drug - males with carcinoma of the breast - males with known or suspected carcinoma of the prostate gland - women who are pregnant (see precautions, pregnancy) - patients with serious cardiac, hepatic or renal disease (see warnings) testosterone cypionate injection contains testosterone, a schedule iii controlled substance in th